Download PDF
Semin Thromb Hemost 2013; 39(07): 752-766
DOI: 10.1055/s-0033-1356715
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Systematic Review of the Role of FVIII Concentrates in Inhibitor Development in Previously Untreated Patients with Severe Hemophilia A: A 2013 Update

Massimo Franchini
1   Department of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantova, Italy
,
Antonio Coppola
2   Regional Reference Center for Coagulation Disorders, Federico II University Hospital, Naples, Italy
,
Angiola Rocino
3   Hemophilia and Thrombosis Center, San Giovanni Bosco Hospital, Naples, Italy
,
Elena Santagostino
4   Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Cà Granda Foundation, Maggiore Hospital Policlinico, Milan, Italy
,
Annarita Tagliaferri
5   Regional Reference Centre for Inherited Bleeding Disorders, University Hospital, Parma, Italy
,
Ezio Zanon
6   Department of Cardiologic, Haemophilia Centre, Thoracic and Vascular Sciences, University of Padua Medical School, Padua, Italy
,
Massimo Morfini
7   Department of Emergency & Reception, Agency for Haemophilia, Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy
,
; Italian Association of Hemophilia Centers (AICE) Working Group › Author Affiliations
Further Information

Publication History

Publication Date:
10 September 2013 (online)

    Permissions and Reprints

Abstract

Nowadays, patients with hemophilia A receive a high standard of care; therefore, the most challenging complication of factor VIII (FVIII) replacement therapy has become the development of FVIII inhibitors, which render the concentrate infusion ineffective and expose patients to an increased risk of morbidity and mortality. Among environmental risk factors influencing inhibitor development, the type of FVIII products has always drawn the attention of investigators. Conflicting results are reported in the literature concerning rates of inhibitor development after either plasma-derived or recombinant FVIII concentrates. To help elucidate this controversial issue, we have performed a systematic review and meta-analysis of prospective studies evaluating the incidence of inhibitors in previously untreated patients with severe hemophilia A receiving plasma-derived or recombinant FVIII products. The quality of the studies was assessed using the Newcastle–Ottawa Scale (NOS), the STrenghtening the Reporting of OBservational studies in Epidemiology and an ad hoc quality score. Overall, 28 prospective studies, including 1,421 patients with hemophilia A, fulfilled our selection criteria and were included in the systematic review. No statistically significant differences were observed in the inhibitor incidence between plasma-derived and recombinant FVIII concentrates considering all (weighted means: 23%, 95% CI: 15–33% vs. 29%, 95% CI: 26–32%) and high titer (16%, 95% CI: 10–26% vs. 18%, 95% CI: 15–21%) inhibitors. Similarly, no significant differences were found in the inhibitor incidence among the different classes of recombinant products. In conclusion, the results of our meta-analysis show that the different types of FVIII products are not associated with different risks of inhibitor development.

Keywords

plasma derived - recombinant - FVIII concentrates - inhibitors - bleeding - therapy - systematic review

Supplementary Material

 

  • References

  • 1 Mannucci PM, Tuddenham EG. The hemophilias—from royal genes to gene therapy. N Engl J Med 2001; 344 (23) 1773-1779
    CrossrefPubMedGoogle Scholar
  • 2 Franchini M, Coppola A, Molinari AC , et al. Forum on: the role of recombinant factor VIII in children with severe haemophilia A. Haemophilia 2009; 15 (2) 578-586
    CrossrefPubMedGoogle Scholar
  • 3 Franchini M, Mannucci PM. Past, present and future of hemophilia: a narrative review. Orphanet J Rare Dis 2012; 7: 24
    CrossrefPubMedGoogle Scholar
  • 4 Coppola A, Franchini M, Tagliaferri A. Prophylaxis in people with haemophilia. Thromb Haemost 2009; 101 (4) 674-681
    PubMedGoogle Scholar
  • 5 Gringeri A, Mantovani LG, Scalone L, Mannucci PM ; COCIS Study Group. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102 (7) 2358-2363
    CrossrefPubMedGoogle Scholar
  • 6 Darby SC, Keeling DM, Spooner RJ , et al; UK Haemophilia Centre Doctors' Organisation. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. J Thromb Haemost 2004; 2 (7) 1047-1054
    CrossrefPubMedGoogle Scholar
  • 7 Schwaab R, Brackmann HH, Meyer C , et al. Haemophilia A: mutation type determines risk of inhibitor formation. Thromb Haemost 1995; 74 (6) 1402-1406
    PubMedGoogle Scholar
  • 8 Gouw SC, van den Berg HM, Oldenburg J , et al. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood 2012; 119 (12) 2922-2934
    CrossrefPubMedGoogle Scholar
  • 9 Astermark J, Oldenburg J, Escobar M, White II GC, Berntorp E ; Malmö International Brother Study study group. The Malmö International Brother Study (MIBS). Genetic defects and inhibitor development in siblings with severe hemophilia A. Haematologica 2005; 90 (7) 924-931
    PubMedGoogle Scholar
  • 10 Viel KR, Ameri A, Abshire TC , et al. Inhibitors of factor VIII in black patients with hemophilia. N Engl J Med 2009; 360 (16) 1618-1627
    CrossrefPubMedGoogle Scholar
  • 11 Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert AK ; MIBS Study Group. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood 2006; 107 (8) 3167-3172
    CrossrefPubMedGoogle Scholar
  • 12 Astermark J, Oldenburg J, Carlson J , et al. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 2006; 108 (12) 3739-3745
    CrossrefPubMedGoogle Scholar
  • 13 Santagostino E, Mancuso ME, Rocino A , et al. Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol 2005; 130 (3) 422-427
    CrossrefPubMedGoogle Scholar
  • 14 Gouw SC, van der Bom JG, Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007; 109 (11) 4648-4654
    CrossrefPubMedGoogle Scholar
  • 15 Franchini M, Lippi G. Von Willebrand factor-containing factor VIII concentrates and inhibitors in hemophilia A: A critical literature review. Thromb Haemost 2010; 104 (5) 931-940
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Chambost H. Assessing risk factors: prevention of inhibitors in haemophilia. Haemophilia 2010; 16 (Suppl. 02) 10-15
    CrossrefPubMedGoogle Scholar
  • 17 Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9 (4) 418-435
    CrossrefPubMedGoogle Scholar
  • 18 Iorio A, Halimeh S, Holzhauer S , et al. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. J Thromb Haemost 2010; 8 (6) 1256-1265
    CrossrefPubMedGoogle Scholar
  • 19 Franchini M, Tagliaferri A, Mengoli C, Cruciani M. Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: a critical systematic review. Crit Rev Oncol Hematol 2012; 81 (1) 82-93
    CrossrefPubMedGoogle Scholar
  • 20 European Medicines Agency. Report of expert meeting on FVIII products and inhibitor development. 28 February – 2 March 2006. Doc Ref. EMEA/CHMP/BPWP/12835/2006. London, 22 February 2007. Available at http://www.emea.europa.eu/docs/en_GB/document_library/Report/2009/11/WC500015512.pdf Last accessed May 21, 2013.
    PubMedGoogle Scholar
  • 21 White II GC, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J ; Factor VIII and Factor IX Subcommittee. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85 (3) 560
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Rothschild C, Gill J, Scharrer I, Bray G. Transient inhibitors in the Recombinate PUP study. Thromb Haemost 2000; 84 (1) 145-146
    PubMedGoogle Scholar
  • 23 Brant R. Assessing proportionality in the proportional odds model for ordinal logistic regression. Biometrics 1990; 46 (4) 1171-1178
    CrossrefPubMedGoogle Scholar
  • 24 von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP ; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370 (9596) 1453-1457
    CrossrefPubMedGoogle Scholar
  • 25 Wells GA, Shea B, O'Connell D , et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. Available at http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm . (last visit 14–03–2013).
    PubMed
  • 26 Lusher JM, Salzman PM ; The Monoclate Study Group. Viral safety and inhibitor development associated with factor VIIIC ultra-purified from plasma in hemophiliacs previously unexposed to factor VIIIC concentrates. Semin Hematol 1990; 27 (2) (Suppl. 02) 1-7
    PubMedGoogle Scholar
  • 27 Lusher JM. Viral safety and inhibitor development associated with monoclonal antibody-purified F VIII C. Ann Hematol 1991; 63 (3) 138-141
    CrossrefPubMedGoogle Scholar
  • 28 Ehrenforth S, Kreuz W, Scharrer I , et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339 (8793) 594-598
    CrossrefPubMedGoogle Scholar
  • 29 Ljung R, Petrini P, Lindgren AC, Tengborn L, Nilsson IM. Factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339 (8808) 1550
    CrossrefPubMedGoogle Scholar
  • 30 Addiego Jr JE-J, Gomperts E, Liu SL , et al. Treatment of hemophilia A with a highly purified factor VIII concentrate prepared by anti-FVIIIc immunoaffinity chromatography. Thromb Haemost 1992; 67 (1) 19-27
    PubMedGoogle Scholar
  • 31 de Biasi R, Rocino A, Papa ML, Salerno E, Mastrullo L, De Blasi D. Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates. Thromb Haemost 1994; 71 (5) 544-547
    PubMedGoogle Scholar
  • 32 Yee TT, Williams MD, Hill FG, Lee CA, Pasi KJ. Absence of inhibitors in previously untreated patients with severe haemophilia A after exposure to a single intermediate purity factor VIII product. Thromb Haemost 1997; 78 (3) 1027-1029
    PubMedGoogle Scholar
  • 33 ElAlfy MS, Tantawy AA, Ahmed MH, Abdin IA. Frequency of inhibitor development in severe haemophilia A children treated with cryoprecipitate and low-dose immune tolerance induction. Haemophilia 2000; 6 (6) 635-638
    CrossrefPubMedGoogle Scholar
  • 34 Klukowska A, Komrska V, Jansen M, Laguna P. Low incidence of factor VIII inhibitors in previously untreated patients during prophylaxis, on-demand treatment and surgical procedures, with Octanate®: interim report from an ongoing prospective clinical study. Haemophilia 2011; 17 (3) 399-406
    CrossrefPubMedGoogle Scholar
  • 35 Mauser-Bunschoten EP, van der Bom JG, Bongers M , et al. Purity of factor VIII product and incidence of inhibitors in previously untreated patients with haemophilia A. Haemophilia 2001; 7 (4) 364-368
    CrossrefPubMedGoogle Scholar
  • 36 Kreuz W, Ettingshausen CE, Zyschka A , et al. Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products. Semin Thromb Hemost 2002; 28 (3) 285-290
    Article in Thieme ConnectPubMedGoogle Scholar
  • 37 Gouw SC, van der Bom JG, Ljung R , et al; PedNet and RODIN Study Group. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med 2013; 368 (3) 231-239
    CrossrefPubMedGoogle Scholar
  • 38 Bray GL, Gomperts ED, Courter SG , et al; The Recombinate Study Group. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. Blood 1994; 83 (9) 2428-2435
    PubMedGoogle Scholar
  • 39 Gruppo R, Chen H, Schroth P, Bray GL. Safety and immunogenicity of recombinant factor VIII (Recombinate) in previously untreated patients: a 7.3 year update. Haemophilia 1998; 4: 228 (abstract no. 291, XXIII Congress of the WFH, The Hague).
    PubMedGoogle Scholar
  • 40 Goodeve AC, Williams I, Bray GL, Peake IR ; Recombinate PUP Study Group. Relationship between factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with recombinant factor VIII (Recombinate). Thromb Haemost 2000; 83 (6) 844-848
    PubMedGoogle Scholar
  • 41 Rothschild C, Laurian Y, Satre EP , et al. French previously untreated patients with severe hemophilia A after exposure to recombinant factor VIII : incidence of inhibitor and evaluation of immune tolerance. Thromb Haemost 1998; 80 (5) 779-783
    Article in Thieme ConnectPubMedGoogle Scholar
  • 42 Lusher JM, Arkin S, Abildgaard CF, Schwartz RS ; Kogenate Previously Untreated Patient Study Group. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. N Engl J Med 1993; 328 (7) 453-459
    CrossrefPubMedGoogle Scholar
  • 43 Lusher J, Abildgaard C, Arkin S , et al. Human recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigation. J Thromb Haemost 2004; 2 (4) 574-583
    CrossrefPubMedGoogle Scholar
  • 44 Yoshioka A, Fukutake K, Takamatsu J, Shirahata A ; Kogenate Post-Marketing Surveillance Study Group. Clinical evaluation of a recombinant factor VIII preparation (Kogenate) in previously untreated patients with hemophilia A. Int J Hematol 2003; 78 (5) 467-474
    CrossrefPubMedGoogle Scholar
  • 45 Giangrande PLF ; KOGENATE Bayer Study Group. Safety and efficacy of KOGENATE Bayer in previously untreated patients (PUPs) and minimally treated patients (MTPs). Haemophilia 2002; 8 (Suppl. 02) 19-22
    CrossrefPubMedGoogle Scholar
  • 46 Kreuz W, Gill JC, Rothschild C , et al; International Kogenate-FS Study Group. Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation. Thromb Haemost 2005; 93 (3) 457-467
    PubMedGoogle Scholar
  • 47 Oldenburg J, Ivaskevicius V, Schröder J, Müller CR, Ganguly A. Genetic background and inhibitors in previously untreated or minimally treated young patients with severe haemophilia A treated with sucrose-formulated recombinant factor VIII. Thromb Haemost 2006; 95 (5) 903-905
    PubMedGoogle Scholar
  • 48 Musso R, Santagostino E, Faradji A , et al; KOGENATE Bayer European PMS Study Group. Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting. Thromb Haemost 2008; 99 (1) 52-58
    PubMedGoogle Scholar
  • 49 Lusher JM, Lee CA, Kessler CM, Bedrosian CL ; ReFacto Phase 3 Study Group. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia 2003; 9 (1) 38-49
    PubMedGoogle Scholar
  • 50 Lusher JM, Roth DA. The safety and efficacy of B-domain deleted recombinant factor VIII concentrates in patients with severe haemophilia A: an update. Haemophilia 2005; 11 (3) 292-293
    CrossrefPubMedGoogle Scholar
  • 51 Courter SG, Bedrosian CL. Clinical evaluation of B-domain deleted recombinant factor VIII in previously untreated patients. Semin Hematol 2001; 38 (2) (Suppl. 04) 52-59
    CrossrefPubMedGoogle Scholar
  • 52 Pollmann H, Externest D, Ganser A , et al. Efficacy, safety and tolerability of recombinant factor VIII (REFACTO) in patients with haemophilia A: interim data from a postmarketing surveillance study in Germany and Austria. Haemophilia 2007; 13 (2) 131-143
    CrossrefPubMedGoogle Scholar
  • 53 Auerswald G, Thompson AA, Recht M , et al. Experience of Advate rAHF-PFM in previously untreated patients and minimally treated patients with haemophilia A. Thromb Haemost 2012; 107 (6) 1072-1082
    Article in Thieme ConnectPubMedGoogle Scholar
  • 54 Schwarzinger I, Pabinger I, Korninger C , et al. Incidence of inhibitors in patients with severe and moderate hemophilia A treated with factor VIII concentrates. Am J Hematol 1987; 24 (3) 241-245
    CrossrefPubMedGoogle Scholar
  • 55 McMillan CW, Shapiro SS, Whitehurst D, Hoyer LW, Rao AV, Lazerson J. The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors. Blood 1988; 71 (2) 344-348
    PubMedGoogle Scholar
  • 56 Schwartz RS, Abildgaard CF, Aledort LM , et al. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group. N Engl J Med 1990; 323 (26) 1800-1805
    CrossrefPubMedGoogle Scholar
  • 57 Rasi V, Ikkala E. Haemophiliacs with factor VIII inhibitors in Finland: prevalence, incidence and outcome. Br J Haematol 1990; 76 (3) 369-371
    CrossrefPubMedGoogle Scholar
  • 58 Fukui H, Yoshioka A, Shima M , et al. Clinical evaluation of recombinant human factor VIII (BAY w 6240) in the treatment of hemophilia A. Int J Hematol 1991; 54 (5) 419-427
    PubMedGoogle Scholar
  • 59 Fukui H, Mori K, Ishikawa M , et al. A long-term, multi-center clinical study of recombinant human factor VIII (BAY w 6240) in the treatment of hemophilia A. . [in Japanese] Nihon Yuketsu Gakkai Zasshi. 1991; 37: 593-604
    PubMedGoogle Scholar
  • 60 Lorenzo JI, Garcia R, Molina R. Factor VIII and Factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 1550-1551
    CrossrefPubMedGoogle Scholar
  • 61 Addiego J, Kasper C, Abildgaard C , et al. Inhibitors in factor VIII deficient hemophilia: Comparison of frequency based upon treatment. Blood 1992; 80 (Suppl. 01) 231 (Abstract)
    PubMedGoogle Scholar
  • 62 Sultan Y ; French Hemophilia Study Group. Prevalence of inhibitors in a population of 3435 hemophilia patients in France. Thromb Haemost 1992; 67 (6) 600-602
    PubMedGoogle Scholar
  • 63 Rosendaal FR, Nieuwenhuis HK, van den Berg HM , et al; Dutch Hemophilia Study Group. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Blood 1993; 81 (8) 2180-2186
    PubMedGoogle Scholar
  • 64 Peerlinck K, Rosendaal FR, Vermylen J. Incidence of inhibitor development in a group of young hemophilia A patients treated exclusively with lyophilized cryoprecipitate. Blood 1993; 81 (12) 3332-3335
    PubMedGoogle Scholar
  • 65 Addiego J, Kasper C, Abildgaard C , et al. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII. Lancet 1993; 342 (8869) 462-464
    CrossrefPubMedGoogle Scholar
  • 66 Peerlinck K, Arnout J, Gilles JG, Saint-Remy JM, Vermylen J. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate. Thromb Haemost 1993; 69 (2) 115-118
    PubMedGoogle Scholar
  • 67 Schimpf K, Schwarz P, Kunschak M. Zero incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex. Thromb Haemost 1995; 73 (3) 553-555
    PubMedGoogle Scholar
  • 68 Guérois C, Laurian Y, Rothschild C , et al. Incidence of factor VIII inhibitor development in severe hemophilia A patients treated only with one brand of highly purified plasma-derived concentrate. Thromb Haemost 1995; 73 (2) 215-218
    PubMedGoogle Scholar
  • 69 Kamiya T, Takahashi I, Saito H. Retrospective study of inhibitor formation in Japanese hemophiliacs. Int J Hematol 1995; 62 (3) 175-181
    CrossrefPubMedGoogle Scholar
  • 70 White II GCII, Courter S, Bray GL, Lee M, Gomperts ED ; The Recombinate Previously Treated Patient Study Group. A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. Thromb Haemost 1997; 77 (4) 660-667
    PubMedGoogle Scholar
  • 71 Muntean W, Male C, Streif W , et al. Low inhibitor incidence in children treated with pasteurised human factor VIII. Thromb Haemost 1997; (Suppl. 01) 647 (abstract)
    PubMedGoogle Scholar
  • 72 Aygören-Pürsün E, Scharrer I ; German Kogenate Study Group. A multicenter pharmacosurveillance study for the evaluation of the efficacy and safety of recombinant factor VIII in the treatment of patients with hemophilia A. Thromb Haemost 1997; 78 (5) 1352-1356
    PubMedGoogle Scholar
  • 73 Lusher J, Arkin S, Abildgaard C, Hurst D. Recombinant FVIII (Kogenate) treatment of previously untreated patients (PUPs) with hemophilia A—update of safety, efficacy and inhibitor development after 7 study years. Thromb Haemost 1997; 78 (Suppl. ): 162
    PubMedGoogle Scholar
  • 74 Peerlinck K, Arnout J, Di Giambattista M , et al. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate. Thromb Haemost 1997; 77 (1) 80-86
    PubMedGoogle Scholar
  • 75 Giles AR, Rivard GE, Teitel J, Walker I. Surveillance for factor VIII inhibitor development in the Canadian Hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy. Transfus Sci 1998; 19 (2) 139-148
    CrossrefPubMedGoogle Scholar
  • 76 Goudemand J, D'Oiron R, Rothschild C , et al. Incidence des inhibiteurs anti-F VIII chez des patients traits par facteur VIII–LFB. Sang Thromb Vaiss 1998; 10: 77-81
    PubMedGoogle Scholar
  • 77 Baglin T, Beacham E. Is a change of factor VIII product a risk factor for the development of a factor VIII inhibitor?. Thromb Haemost 1998; 80 (6) 1036-1037
    PubMedGoogle Scholar
  • 78 Seremetis S, Lusher JM, Abildgaard CF, Kasper CK, Allred R, Hurst D ; The KOGENATE Study Group. Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5-year study of home therapy. Haemophilia 1999; 5 (1) 9-16
    CrossrefPubMedGoogle Scholar
  • 79 Lusher JM, Kreuz W, Gazengel C , et al. Inhibitor formation monitoring in pediatric patients with severe hemophilia A receiving a second-generation rFVIII concentrate formulated with sucrose. Blood 1999; 94 (Suppl. 01) 237 (Abstract)
    PubMedGoogle Scholar
  • 80 Rokicka-Milewska R, Klukowska A, Dreger B, Beer HJ. Incidence of factor VIII inhibitor development in previously untreated haemophilia A patients after exposure to a double virus inactivated factor VIII concentrate. Ann Hematol 1999; 78 (Suppl. 01) A10 (abstract)
    PubMedGoogle Scholar
  • 81 Yee TT, Pasi KJ, Lilley PA, Lee CA. Factor VIII inhibitors in haemophiliacs: a single-centre experience over 34 years, 1964-97. Br J Haematol 1999; 104 (4) 909-914
    CrossrefPubMedGoogle Scholar
  • 82 Abshire TC, Brackmann HH, Scharrer I , et al. Sucrose formulated recombinant human antihemophilic factor VIII is safer and efficacious for treatment of hemophilia A in home therapy. Thromb Haemost 2000; 83: 811-816
    PubMedGoogle Scholar
  • 83 Shirahata A, Fukutake K, Takamatsu J, Shima M, Yoshioka A. Pharmacokinetics, prophylactic effects, and safety of a new recombinant FVIII formulated with sucrose (BAY 14-2222) in Japanese patients with hemophilia A. Int J Hematol 2000; 72 (1) 101-107
    PubMedGoogle Scholar
  • 84 Yoshioka A, Shima M, Fukutake K, Takamatsu J, Shirahata A ; Coganate FS Study Group. Safety and efficacy of a new recombinant FVIII formulated with sucrose (rFVIII-FS) in patients with haemophilia A: a long-term, multicentre clinical study in Japan. Haemophilia 2001; 7 (3) 242-249
    CrossrefPubMedGoogle Scholar
  • 85 Lorenzo JI, López A, Altisent C, Aznar JA. Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age. Br J Haematol 2001; 113 (3) 600-603
    CrossrefPubMedGoogle Scholar
  • 86 Rothschild C, Scharrer I, Brackmann HH , et al. European data of a clinical trial with a sucrose formulated recombinant factor VIII in previously treated haemophilia A patients. Haemophilia 2002; 8 (Suppl. 02) 10-14
    CrossrefPubMedGoogle Scholar
  • 87 van der Bom JG, Mauser-Bunschoten EP, Fischer K, van den Berg HM. Age at first treatment and immune tolerance to factor VIII in severe hemophilia. Thromb Haemost 2003; 89 (3) 475-479
    PubMedGoogle Scholar
  • 88 Gringeri A, Tagliaferri A, Tagariello G, Morfini M, Santagostino E, Mannucci P ; ReFacto-AICE Study Group. Efficacy and inhibitor development in previously treated patients with haemophilia A switched to a B domain-deleted recombinant factor VIII. Br J Haematol 2004; 126 (3) 398-404
    CrossrefPubMedGoogle Scholar
  • 89 Ewenstein BM, Gomperts ED, Pearson S, O'Banion ME. Inhibitor development in patients receiving recombinant factor VIII (Recombinate rAHF/Bioclate): a prospective pharmacovigilance study. Haemophilia 2004; 10 (5) 491-498
    CrossrefPubMedGoogle Scholar
  • 90 Tarantino MD, Collins PW, Hay CR , et al; RAHF-PFM Clinical Study Group. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia 2004; 10 (5) 428-437
    CrossrefPubMedGoogle Scholar
  • 91 Morado M, Villar A, Jiménez Yuste V, Quintana M, Hernandez Navarro F. Prophylactic treatment effects on inhibitor risk: experience in one centre. Haemophilia 2005; 11 (2) 79-83
    CrossrefPubMedGoogle Scholar
  • 92 Smith MP, Giangrande P, Pollman H, Littlewood R, Kollmer C, Feingold J ; Refacto St Louis Study Group. A postmarketing surveillance study of the safety and efficacy of ReFacto (St Louis-derived active substance) in patients with haemophilia A. Haemophilia 2005; 11 (5) 444-451
    CrossrefPubMedGoogle Scholar
  • 93 Kreuz W, Auerswald G, Budde U, Lenk H. The GTH-PUP-Study Group. In: Scharrer I, Schramm W, , eds. Inhibitor Development in Previously Treated Patients (PUPs) with Haemophilia A and B. A Prospective Multicentre Study of the German, Swiss and Austrian Society of Thrombosis and Haemostasis Research (GTH). 35th Haemophilia Symposium, Hamburg 2004. Heidelberg, Germany: Springer Verlag; 2005: 34-37
    Google Scholar
  • 94 Gringeri A, Monzini M, Tagariello G, Scaraggi FA, Mannucci PM ; Emoclot15 Study Members. Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate. Haemophilia 2006; 12 (2) 128-132
    PubMedGoogle Scholar
  • 95 Goudemand J, Rothschild C, Demiguel V , et al; FVIII-LFB and Recombinant FVIII study groups. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006; 107 (1) 46-51
    CrossrefPubMedGoogle Scholar
  • 96 Kempton CL, Soucie JM, Abshire TC. Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates. J Thromb Haemost 2006; 4 (12) 2576-2581
    CrossrefPubMedGoogle Scholar
  • 97 Gouw SC, van den Berg HM, le Cessie S, van der Bom JG. Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A. J Thromb Haemost 2007; 5 (7) 1383-1390
    CrossrefPubMedGoogle Scholar
  • 98 Shi J, Zhao Y, Wu J, Sun J, Wang L, Yang R. Safety and efficacy of a sucrose-formulated recombinant factor VIII product for the treatment of previously treated patients with haemophilia A in China. Haemophilia 2007; 13 (4) 351-356
    CrossrefPubMedGoogle Scholar
  • 99 Singleton E, Smith J, Kavanagh M, Nolan B, White B. Low risk of inhibitor formation in haemophilia patients after a change in treatment from Chinese hamster ovary cell-produced to baby hamster kidney cell-produced recombinant factor VIII. Thromb Haemost 2007; 98 (6) 1188-1192
    PubMedGoogle Scholar
  • 100 Chalmers EA, Brown SA, Keeling D , et al; Paediatric Working Party of UKHCDO. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A. Haemophilia 2007; 13 (2) 149-155
    CrossrefPubMedGoogle Scholar
  • 101 Gouw SC, van der Bom JG, Auerswald G, Ettinghausen CE, Tedgård U, van den Berg HM. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 2007; 109 (11) 4693-4697
    CrossrefPubMedGoogle Scholar
  • 102 Delumeau JC, Ikegawa C, Yokoyama C, Haupt V. An observational study of sucrose-formulated recombinant factor VIII for Japanese patients with haemophilia A. Thromb Haemost 2008; 100 (1) 32-37
    PubMedGoogle Scholar
  • 103 Rubinger M, Lillicrap D, Rivard GE , et al; Association of Hemophilia Clinic Directors of Canada. A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose. Haemophilia 2008; 14 (2) 281-286
    CrossrefPubMedGoogle Scholar
  • 104 Boekhorst J, Lari GR, D'Oiron R , et al. Factor VIII genotype and inhibitor development in patients with haemophilia A: highest risk in patients with splice site mutations. Haemophilia 2008; 14 (4) 729-735
    CrossrefPubMedGoogle Scholar
  • 105 Blanchette VS, Shapiro AD, Liesner RJ , et al; rAHF-PFM Clinical Study Group. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost 2008; 6 (8) 1319-1326
    CrossrefPubMedGoogle Scholar
  • 106 Strauss T, Ravid B, Martinowitz U, Bashari D, Kenet G. Early exposure to recombinant factor concentrates may increase inhibitor development: a single center cohort study. Haemophilia 2008; 14 (Suppl. 02) 52 (abstract)
    CrossrefPubMedGoogle Scholar
  • 107 Bajwa N, Enriquez MM, Gorina E, Lemm G. Cumulative analysis of inhibitor formation in patients with haemophilia A treated with sucrose-formulated recombinant factor VIII. Haemophilia 2009; 15 (2) 597-600
    CrossrefPubMedGoogle Scholar
  • 108 Young JH, Liu HC, Hsueh EJ , et al. Efficacy and safety evaluation of sucrose-formulated recombinant factor VIII for Taiwanese patients with haemophilia A. Haemophilia 2009; 15 (4) 968-970
    CrossrefPubMedGoogle Scholar
  • 109 Recht M, Nemes L, Matysiak M , et al. Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII. Haemophilia 2009; 15 (4) 869-880
    CrossrefPubMedGoogle Scholar
  • 110 Bidlingmaier C, Manner D, Halimeh S , et al. Influence of factor VIII products, viral inactivation and dosage regimens on meaningful inhibitor development in children with severe hemophilia A: results of a non-concurrent cohort study. J Thromb Haemost 2009; 7 (Suppl. 02) 525 (abstract)
    PubMedGoogle Scholar
  • 111 Den Uijl I, Mauser-Bunschoten EP, Roosendaal G, Schutgens R, Fischer K. Efficacy assessment of a new clotting factor concentrate in haemophilia A patients, including prophylactic treatment. Haemophilia 2009; 15 (6) 1215-1218
    CrossrefPubMedGoogle Scholar
  • 112 Collins P, Faradji A, Morfini M, Enriquez MM, Schwartz L. Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study. J Thromb Haemost 2010; 8 (1) 83-89
    CrossrefPubMedGoogle Scholar
  • 113 Oldenburg J, Goudemand J, Valentino L , et al. Postauthorization safety surveillance of ADVATE [antihaemophilic factor (recombinant), plasma/albumin-free method] demonstrates efficacy, safety and low-risk for immunogenicity in routine clinical practice. Haemophilia 2010; 16 (6) 866-877
    CrossrefPubMedGoogle Scholar
  • 114 Vidovic N, Musso R, Klamroth R, Enriquez MM, Achilles K. Postmarketing surveillance study of KOGENATE Bayer with Bio-Set in patients with haemophilia A: evaluation of patients' satisfaction after switch to the new reconstitution system. Haemophilia 2010; 16 (1) 66-71
    CrossrefPubMedGoogle Scholar
  • 115 Bacon CL, Singleton E, Brady B , et al. Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE®). Haemophilia 2011; 17 (3) 407-411
    CrossrefPubMedGoogle Scholar
  • 116 Dmoszynska A, Kuliczkowski K, Hellmann A , et al. Clinical assessment of Optivate®, a high-purity concentrate of factor VIII with von Willebrand factor, in the management of patients with haemophilia A. Haemophilia 2011; 17 (3) 456-462
    CrossrefPubMedGoogle Scholar
  • 117 Gringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci PM ; ESPRIT Study Group. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011; 9 (4) 700-710
    CrossrefPubMedGoogle Scholar
  • 118 Matysiak M, Bobrowska H, Balwierz W , et al. Clinical experience with Optivate®, high-purity factor VIII (FVIII) product with von Willebrand factor (VWF) in young children with haemophilia A. Haemophilia 2011; 17 (5) 737-742
    PubMedGoogle Scholar
  • 119 Klukowska A, Windyga J, Batorova A. Clinical efficacy of a novel VWF-containing FVIII concentrate, Wilate(®), in the prophylaxis and treatment of bleeding episodes in previously treated haemophilia A patients. Thromb Res 2011; 127 (3) 247-253
    CrossrefPubMedGoogle Scholar
  • 120 Zhang L, Zhao Y, Sun J, Wang X, Yu M, Yang R. Clinical observation on safety and efficacy of a plasma- and albumin-free recombinant factor VIII for on-demand treatment of Chinese patients with haemophilia A. Haemophilia 2011; 17 (2) 191-195
    CrossrefPubMedGoogle Scholar
  • 121 Maclean PS, Richards M, Williams M , et al; Paediatric Working Party of UKHCDO. Treatment related factors and inhibitor development in children with severe haemophilia A. Haemophilia 2011; 17 (2) 282-287
    CrossrefPubMedGoogle Scholar
  • 122 Strauss T, Lubetsky A, Ravid B , et al. Recombinant factor concentrates may increase inhibitor development: a single centre cohort study. Haemophilia 2011; 17 (4) 625-629
    CrossrefPubMedGoogle Scholar
  • 123 Shirahata A, Fukutake K, Higasa S , et al; Study Group on Factors Involved in Formation of Inhibitors to Factor VIII and IX Preparations. An analysis of factors affecting the incidence of inhibitor formation in patients with congenital haemophilia in Japan. Haemophilia 2011; 17 (5) 771-776
    PubMedGoogle Scholar
  • 124 Mancuso ME, Mannucci PM, Rocino A, Garagiola I, Tagliaferri A, Santagostino E. Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A. J Thromb Haemost 2012; 10 (5) 781-790
    CrossrefPubMedGoogle Scholar
  • 125 Pollmann H, Klamroth R, Vidovic N , et al. Prophylaxis and quality of life in patients with hemophilia A during routine treatment with ADVATE [antihemophilic factor (recombinant), plasma/albumin-free method] in Germany: a subgroup analysis of the ADVATE PASS post-approval, non-interventional study. Ann Hematol 2013; 92 (5) 689-698
    CrossrefPubMedGoogle Scholar
  • 126 Mannucci PM, Gringeri A, Peyvandi F, Santagostino E. Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers). Haemophilia 2007; 13 (Suppl. 05) 65-68
    CrossrefPubMedGoogle Scholar